Lucid Group LCID Assessing the RiskReward Opportunity at Its MultiYear Price Low Eli Lilly and Company LLY Announces 23B Planned Acquisition of Ajax Therapeutics to Bolster Hematological Oncology Pipeline ABEV Ambev posts narrow Q4 2025 earnings beat shares fall 204 percent on muted investor sentiment